Moreover, while providing equivalent anti-tumour efficacy, IMS protocol allows us to reduce the cumulative amount of administered anti-PD-1, reducing the risk of development of dose-dependent autoimmune response [37]. This evidence concerns the gene PDCD1 and neoplasm.